+34 620 10 75 37info@nanbiosis.com

News U10

News U10

You are here : Home / News U10 (Page 3)

Moore4Medical a project to accelerate innovation in electronic medical devices

The NanoBioCell group, led by Prof. Jose Luis Pedraz, participates in the European project Moore4medical. A project to accelerate innovation in emergencing medical devices with open tecnhology platforms. The NanoBiocel group, will focus on the lyophilization process of biopharmaceuticals and their use in microfluidic devices

The NanoBiocel research group of the University of the Basque Country / Euskal Herriko Unibertsitatea, which is part of the CIBER BBN and the ICTS Nanbiosis through the U10 Drug Formulation Unit, and led by Professor Jose Luis Pedraz of the Faculty of Pharmacy, participates in the European project Moore4medical, which aims to accelerate innovation in electronic and microfabricated devices for several emerging medical specialties. Specifically, the work of the NanoBiocel group will focus on optimizing the lyophilization process of biopharmaceuticals in microfluidic devices.
The three-year Moore4Medical project is funded by the public-private partnership ECSEL (Electronic Components and Systems for European Leadership), which manages a research and innovation program to strengthen the electronic components and systems sector to maintain to the European Union at the forefront of technological development. The total financing of the project amounts to € 68M, of which more than half a million have been awarded to the work of NanoBiocel.
In Moore4Medical, 68 partners participate (between private companies, universities and research institutions) from 13 countries and is led by the Dutch multinational Philips in its electronics and medical systems and service innovation divisions.

Microfluidic device
The NanoBioCell group will work, together with the Mondragón company microLIQUID, in the development of technology for integrating lyophilized drugs and their rehydration in a microfluidic device for their correct administration. The lyophilized drug will be integrated into the microfluidic device using specific techniques to ensure a good interaction between the fluid and the drug for delivery by the pump. The final objective is to design a system for the administration of drugs by parenteral route that is much more comfortable for patients and that improves the therapeutic compliance of treatments.
The microLIQUID company is a leading biotechnology company in the microfluidic technologies sector and will be in charge of the design and development of microfluidic modules.
In this work called ‘Drug Adherence’, integrated within the total project, the NanoBioCel group will team up with the Irish national institute Tyndall, the multinational pharmaceutical company AbbVie, the Fraunhofer Institute of Germany, the service innovation section of Philips, the company German Gaudlitz GmbH, specialist in polymers, the Karlsruhe Technological Institute in Germany and the HI Iberia company in Madrid.

• Read More

Ainhoa González Pujana, NANBIOSIS U10, 2019 best doctoral thesis award by the Bioaraba Research Health Institute

The Bioaraba Health Research Institute has awarded Ainhoa ​​González Pujana, a researcher at NanoBioCell and the Nanbiosis Platform through the U10 Drug Formulation (from CIBER-BBN and UPV-EHU), the award for the best doctoral thesis 2019 at the XXI Bioaraba Research and Innovation Conference, held last November 5 in Vitoria-Gasteiz.

Along with the recognition, the award consists of an economic endowment of € 1,000 in funds for R + D + i. The thesis, directed by Professor Rosa María Hernández and Dr. Edorta Santos Vizcaíno, has been carried out in the NanoBioCel group of the Faculty of Pharmacy of the University of the Basque Country (UPV / EHU). Under the title “Bioinspired three-dimensional multifunctional systems to enhance the therapeutic potential of mesenchymal stromal cells”, the thesis has focused on the design of biomimetic matrices that enhance the immunomodulatory effect of mesenchymal stem cells, as a therapeutic alternative for treatment of the immunological alterations that occur in diseases such as ulcerative colitis, Crohn’s disease or Lupus erythematosus.

• Read More

How to delay vision loss in hereditary retinal dystrophies? Looking for the most effective and economical pharmacological nanotherapy

Researchers from the CIBER-BBN and NANBIOSIS are participating in a new project that aims to achieve the most effective, specific and economical pharmacological nanotherapy that allows delaying the death of retinal cells and subsequent loss of vision in hereditary retinal dystrophy. retinitis pigmentosa, regardless of the genetic defect causing the disease.

In this project, coordinated by the researcher Regina Rodrigo, the ONCE and the Prince Felipe Research Center (CIPF) of Valencia collaborate, together with researchers from the CIBER of Rare Diseases (CIBERER) and the Manises Hospital in Valencia. On behalf of the CIBER-BBN, the scientific director, Ramón Martínez Máñez, together with Elena Aznar from the IDM-UPV group of the Polytechnic University of València, José Luís Pedraz, Gustavo Puras and Idoia Gallego, from the group of the University of the Basque Country and Nanbiosis.

The NANBIOSIS participation in the project will be through the U10 Drug Formulation unit (from @CIBERBBN and @upvehu), led by NanoBioCell Group and Prof. José Luis Pedraz and U26 NMR: Biomedical Applications II , led by IDM-UPV-UV Group, led by Prof. Ramón Martínez Máñez. Elena Aznar, researcher of CIBER-BBN at IDM-UPV-UV explained “We use the unit to characterize the nanoparticles. Through a solid phase NMR confirms that the molecular gate has been correctly attached to the surface of the nanoparticles“.

Retinitis pigmentosa is a group of inherited retinal dystrophies characterized by progressive and irreversible loss of vision. Although it is considered a rare disease, it is the leading genetic cause of blindness in developed countries. So far there is no effective treatment, although there are various therapeutic approaches such as gene therapy, cell therapy, pharmacological therapy, optogenetics or electronic implants.

During the progression of the disease, an important inflammatory component has been observed that may contribute to its pathogenesis. In this sense, different anti-inflammatory strategies have been evaluated. The research group has successfully tested one of these strategies in preclinical models of retinitis pigmentosa. However, the implementation of this therapeutic strategy with nanocarriers as controlled release delivery systems would improve the mode of action of the administered drug, avoiding its degradation, increasing its half-life, stability or its availability in the retina. In this project, two types of nanocarriers will be used and their effect on the degenerative process in a murine model of retinitis pigmentosa will be evaluated.

  • PICTURE: Hematoxylin and eosin image showing that intravitreal blockade of the cytokine TNFα with Adalimumab-type monoclonal antibodies (ADA) reduces retinal degeneration, preventing the death of photoreceptors (RF) in the murine model of retinitis pigmentosa, rd10 mouse.
• Read More

Laura Saenz del Burgo, NANBIOSIS U10, award for the best emerging researcher at the XXI Bioaraba Research and Innovation Conference

The CIBER-BBN researcher at the University of the Basque Country (UPV-EHU), Laura Saenz del Burgo, received, within the framework of the XXI Bioaraba Research and Innovation Conference, the award for the “Best Emerging Researcher 2020”.

The researcher of the NanoBioCel group of the UPV / EHU, who belongs to the CIBER BBN and the U10 Drug Formulation of the ICTS of Nanbiosis, is an active part within the research group led by Jose Luis Pedraz and focuses her work in the areas of Regenerative Medicine , Tissue Engineering and 3D-Bioprinting.

The conference was held at the Palacio de Congresos de Europa, in Vitoria (Álava) last Thursday, November 5. It is a meeting forum between research staff, both from the health system and the university, the company, technology centers, institutions and citizens.

The Bioaraba Research and Innovation Awards want to recognize and encourage people and institutions whose dedication directly affects the improvement of the health and quality of life of the population, through not only purely scientific or healthcare work, but also from a contribution adequate social.

• Read More

Regenerating ankle joints with collagen- and gelatine-based implants

 TRIANKLE is an EU Project to develop regenerative therapies for ankel injuries in which participate NanoBioCell Group and NANBIOSIS U10 Drug Formulation unit (from CIBER-BBN and UPV/EHU), led by José Luis Pedraz.
 The main objective is to reduce the time of recovery down to 50% and
increase the functionality ratios up to 10-15%.
 Research consortium is composed of 12 partners from 5 European countries and counts with a EU funding of €5.9M.
 It is expected that the results of the project will be very well received by potential patients, such as elite athletes and patients with osteoarthritis, through the outreach work of the FCB Barça Innovation Hub and the OAFI, both members of the consortium.

On November 6th, the grant agreement No: 952981 funded by the European
Commission (Horizon 2020 Program) by which the TRIANKLE project comes into operation was signed. The TRIANKLE consortium – made up of 12 European organisations, will develop 3D bioprinted personalised scaffolds for tissue regeneration of ankle joints. This ambitious research project in regenerative medicine comes with an overall budget of €5.9M and
will be developed over 4 years, starting January 2021. The consortium aims to create innovative personalised collagen- and gelatine-based implants manufactured with 3D technology for patients with tendinopathies such as Achilles tendon partial ruptures and cartilage injuries.

Tendinopathies and osteoarthritis (OA) are extremely common and expensive, especially among the elderly, women and professional athletes. In addition to quality of life, both conditions substantially impact healthcare systems of economies worldwide (OA costs €76.5 billion in EU every year, while tendinopathies have an estimated worldwide expenditure above €140,000 million).

Horizon 2020 is the biggest EU Research and Innovation programme ever with nearly €80 billion of funding available over 7 years (2014 to 2020) – in addition to the private investment that this money will attract. It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market.

For more info: http://ec.europa.eu/programmes/horizon2020/en/what-horizon-2020

• Read More

From natural by-products to cell delivery systems for regenerative medicine

Researchers from NANBIOSIS U10 Drug Formulation unit (CIBERBBN – UPV/EHU led Rosa María Hernández, have developed a biomedical device consisting of by-products from the food industry and which displays excellent properties for use in regenerative medicine. The work has been published in the Green Chemistry Jurnal, one of the most prestigious international journals in chemistry and the second most important one in the field of sustainable science. The work has also been selected for the cover page of this issue.

Researchers in the UPV/EHU’s NanoBioCel and Biomat groups have developed a biomedical device consisting of by-products from the food industry and which displays excellent properties for use in regenerative medicine. The novel device comprises soy protein and chitin, which form a matrix with a porous, interconnected microarchitecture similar to that of certain body tissues.

Added to the growing need in recent years to develop new therapies for biomedical applications is the widely called-for social requirement to be environmentally friendly. In this respect, the group of researchers has shown that natural by-products from the food industry, normally discarded in industrial processes, could be an excellent source of biomaterials for producing biomedical devices.

“It is important to point out that to date no one has exploited the potential in regenerative medicine displayed by soy protein and chitin blended in a microporous matrix,” stressed the researchers. “As the first milestone in this respect, this novel device incorporates two natural components obtained from the food industry, thus contributing towards the widely called-for social requirement to upgrade waste from production on an industrial level. The device has also displayed some physico-chemical and mechanical properties suitable for applications in regenerative medicine. What is more, it has also been found to be totally biocompatible not only in in vitro cell lines but also in an in vivo murine model.  Finally, we have confirmed that this device is capable of hosting a large number of viable stem cells inside it, thus increasing its level of bioactive compound secretion and displaying its potential as a very effective vehicle in cell therapy.”

This biotechnological approach may have a potentially successful application in the matrix-based regenerative medicine industry. These devices capable of hosting stem cells are destined to be the revolution, not only in biomedical research but also in everyday clinical practice. “Clinical scenarios as complex as chronic injuries or bone problems need a multifocal approach which combines bioactive matrices with biological agents having regenerative effects,” they concluded.

Article of reference

• Read More

NANBIOSIS researchers featured in the 15th Edition of Spanish Researchers Ranking

The 15th edition of the Webometrics Ranking of World Universities has been published, ranking researchers in Spain as well as Spaniards doing research abroad. A total of 11 Directors of NANBIOSIS units appear on the most recent list, featured on the top 2000. The list is ordered by the h-index, a metric that calculates research impact based on a correlation of papers published and number of citations, and then by number of citations. The result is a list of whose’s publications have had more impact online.

NANBIOSIS researchers featured are Fernando Albericio (#207), scientific director of U3 Synthesis of Peptides Unit, Ramón Martínez Máñez (#342) U26 NMR: Biomedical Applications II, Jaume Veciana (#459) U6 Biomaterial Processing and Nanostructuring Unit, José Luis Pedraz (#906) U10 Drug Formulation unit, Jesús Santamaría (#912) U9 Synthesis of Nanoparticles Unit, Ramón Eritja (#1022) U29 Oligonucleotide Synthesis Platform (OSP), Pablo Laguna (#1153) U27 High Performance Computing, Antoni Villaverde (#1249) U1 Protein Production Platform (PPP), Laura Lechuga (#1511) U4 Biodeposition and Biodetection Unit M.Pilar Marco (#1517), U2 Custom Antibody Service (CAbS), and Josep Samitier (#1836) U7 Nanotechnology Unit.

This list reflects on the impact online publication can have as a tool to share knowledge. 

For further information: here

• Read More

POSITION II WORKSHOP #5 IN LEUVEN, BELGIUM

Jose Luis Pedraz, Jesus Ciriza and Angela Losada of NANBIOSIS U10 Drug Formulation – NanoBioCel Group of CIBER-BBN and University of the Basque Country were in Leuven, Belgium attending the European Project POSITION-II Workshop #5, which was held between January 21 and 23. The workshop was held at the facilities of iMEC, one of the partners of the project and world leader in R&D in nanoelectronics and digital technology.

The project lasts three years and after 18 months, in this workshop, the researchares of NANBIOSIS U10 Drug Formulation, have microencasulated and characterized the heart cells with the aim of checking the viability of the capsules for the treatment. In the next month all the team members of our workpackage (WP7) will meet with purpose of integrating each of the components of the final catheter (assemble them) to proceed with their validation because next year the validation must be done in vivo. 

This work is part of  a pilot line for realising the next generation of smart catheters and implants by building on Europe’s strength in medical diagnostic equipment and monitoring systems.

• Read More

NANBIOSIS Unit 10 expands its equipments and capabilities

NANBIOSIS U10 Drug Formulation unit, led by Dr. José Luis Pedraz, has recently added new equipment as a result of its participation in the project FICTS1420-20, selected by the MINECO for co-financing by the FEDER Program in ICTS 2014-2020.

The new equipment includes:

  • Malvern Spraytec: It’s a laser diffraction system allows measurement of spray particle and spray droplet size distributions, in real time, for more efficient product development of sprays and aerosols.

European Regional Development Fund
• Read More

Agreement signed with Spanish Goverment for the allocation of FEDER funds for NANBIOSIS ICTS

In the framework of the FEDER Program in ICTS 2014-2020, a projects related to the ICTS NANBIOSIS has been selected by the Ministry of Science, Innovation and Universities for co-financing with FEDER funds of the European Regional Development Funds program.

An agreement has been signed between Ministry of Science, Innovation and UPV/EHU (University of the Basque Country ), institution that houses NANBIOSIS unit 10 for the co-financing of the Project FICTS-1420-17: “Purchase and installation and set-up of characterization equipment to complement Unit 10 of drug formulation”.

• Read More